Table 1.
α-Adrenoceptors and the MMP system
| Receptor | Drug | MMP/TIMP | Tissue/Model | Notes | Authors |
|---|---|---|---|---|---|
| α1 | Bunazosin | MMP-2, -3, -9 ↔ | Monkey ciliary muscle cells | 6 h | (Akaishi et al., 2004) |
| α1 | Phenylephrine | MMP-9 ↑ | ECV304 cells | 24 h | (Song et al., 2006) |
| α1 | Noradrenaline; prazosin | MMP-2, TIMP-2 ↑ (NA); ↔ (NA + PRAZ) | Rat ventricular myocardium | 3 to 4 days | (Briest et al., 2004) |
| α1 | Doxazosin | MMP-2, -3, -9 ↔; TIMP-1 ↔ | Human mesangial cells + macrophage medium | 1, 3 days | (Pawluczyk et al., 2006) |
| α1 | Prazosin | MMP-9 ↑ | Rat skeletal muscle | 7 days | (Van Gieson and Skalak, 2001) |
| α1 | Bunazosin | MMP-3 activity ↑, MMP-3 mRNA ↔; MMP-1, -2 ↔; TIMP-1, -3 ↓ | Rat conjunctival tissue, human keratinocytes and fibroblasts | Daily, 2 weeks | (Ito et al., 2006) |
| α1 | 6-Hydroxydopamine; prazosin | TIMP-1 ↓; Liver fibrosis ↓ | CCl4-induced liver fibrosis in rats | 6 weeks | (Dubuisson et al., 2002) |
| α1 | Doxazosin | TIMP-2/MMP-2 ratio ↔ | Aortic-banded rats | 10 weeks | (Perlini et al., 2005) |
| α1 | Terazosin | proMMP-2, MMP-2 ↑; TIMP-1,-2 ↔ | Rat ventral prostate | 120 days | (Mitropoulos et al., 2007) |
| α1 | Anti- α1-adrenoceptor antibody | MMP-2 ↑ | Mouse heart | 1 year | (Zhou et al., 2005) |
| α2 | Brimonidine | proMMP-9 expression ↑, activity ↔; TIMP-4 ↓; proMMP-1, -2, -3, and -24 ↔ | Ciliary body smooth muscle cells | 1 and 3 days | (Ooi et al., 2009) |
| α2 | Brimonidine | MMP-3 ↑; MMP-1, -2 ↔; TIMP-1, -3 ↓ | Rat conjunctival tissue, human keratinocytes and fibroblasts | Daily, 2 weeks | (Ito et al., 2006) |
| α1/2 | Phenoxybenzamine | MMP-2, -9 ↓; TIMP-1 ↑ | Pig vein | 2 weeks | (Chung et al., 2005) |
| ND | Noradrenaline | TIMP-1, -3, MMP-2 ↑ | Mouse heart | 4 h; 1, 3 days | (Meier et al., 2007) |
| ND | Noradrenaline | MMP-2, TIMP-2 ↑ | Rat heart | 3, 4, 7 days | (Briest et al., 2001) |
NA, noradrenaline; ND, not determined; PRAZ, prazosin; ↑, up-regulation; ↔, no effect; ↓, down-regulation.